Shineco (NASDAQ:SISI – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.
Insider and Institutional Ownership
4.1% of Shineco shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 0.0% of Shineco shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Shineco and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shineco | -380.55% | -79.89% | -33.01% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
Gyre Therapeutics has a consensus price target of $16.00, indicating a potential upside of 111.92%. Given Gyre Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Shineco.
Volatility and Risk
Shineco has a beta of -1.76, suggesting that its share price is 276% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.
Earnings and Valuation
This table compares Shineco and Gyre Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
| Gyre Therapeutics | $116.59 million | 7.22 | $5.03 million | ($0.21) | -35.95 |
Gyre Therapeutics has higher revenue and earnings than Shineco. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.
Summary
Gyre Therapeutics beats Shineco on 13 of the 14 factors compared between the two stocks.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Shineco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shineco and related companies with MarketBeat.com's FREE daily email newsletter.
